Latest news for Getlink (OTC:GRPTY) Stock

Getlink SE is a French industrial company focused on road and passenger transportation. The company is organized into four segments: the Eurotunnel segment, the Europorte segment, the ElecLink segment, and the Getlink segment. The Eurotunnel segment contributes the majority of revenue. It includes the shuttle service for vehicles and passengers and payments made for the use of the railway network by high-speed passenger trains (Eurostar) and by train operators' rail freight services. The Europorte rail freight segment includes rail freight subsidiaries across France and the United Kingdom. The ElecLink segment operates an electricity interconnector between France and Great Britain. The company generates majority of the revenue from Eurotunnel segment.

Getlink SE

News

IPOs

Trading Ideas

BCAX

Bicara Therapeutics IPO Open At $26.25/Share; IPO Priced At $18/Share On 17.5M Shares

<p>B of A Securities  analyst Ken Hoexter   maintains World Kinect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WKC#NYSE">WKC</a>) with a Underperform and raises the price target from $24 to $27.</p>


Price Target

Analyst Ratings

B of A Securities Maintains Underperform on World Kinect, Raises Price Target to $27

<p><a href="https://www.semafor.com/article/09/13/2024/how-the-uae-got-the-us-to-bless-its-ai-ambitions">https://www.semafor.com/article/09/13/2024/how-the-uae-got-the-us-to-bless-its-ai-ambitions</a></p>
<p><img src="https://static.semafor.com/_next/static/media/thenews@2x.f322bda2.png" alt="Title icon" /></p>
<h3>The Scoop</h3>
<p>ABU DHABI&nbsp;—&nbsp;The US has approved the sale of cutting-edge Nvidia chips to G42, the company at the center of the United Arab Emirates' efforts to become a global leader in artificial intelligence, according to a person with knowledge of the matter.</p>
<p>The approval, which came earlier this year but has not been reported, is a major milestone for the ambitions of the UAE and the broader Gulf region. The area is becoming an increasingly important global technology hub — but Biden administration concerns about their ties to China have been obstacles to gaining access to key assets, like cutting-edge chips, which face US export curbs to the region.</p>
<p>G42 is only just beginning to deploy the chips, including a sizable order of Nvidia H100 models, but the effort has been years in the making. Long before ChatGPT captivated the world and global demand for Nvidia's most advanced AI chips exploded, the UAE was laying the groundwork to be a serious competitor in the global AI race.</p>
<p>It has made significant, long-term investments in innovations that protect sensitive data, making it exceedingly difficult for anyone but the owner to access. Semafor has learned new details of those efforts, which helped lead US officials to approve the sale of the AI chips.</p>
<p>New data centers in the country are physically locked down and have been built from the ground up with hardware made exclusively by Western nations to avoid the possibility of a Chinese backdoor, people familiar with the matter said.</p>
<p>Older data centers have been stripped of any parts with ties to China, even if those parts are unplugged and not being used.</p>
<p>The compute portion of its data centers, which use military-level FIPS 140-2 encryption, is physically separated from all other systems, from security cameras to cooling. That separation reduces the likelihood that attackers could use vulnerabilities in ancillary hardware to worm their way into the servers.</p>
<p>Customers, workers, and visitors are all screened extensively, and Chinese nationals are not allowed to work at the data centers.</p>
<p>The facilities employ wide-ranging telemetry of everything that happens inside, giving G42 the ability to monitor anomalies in real time, including fluctuations in compute levels that might suggest a customer is building AI models large enough to create national security concerns.</p>
<p>It has also hired US Department of Defense contractors to "red team" its data center defenses to find any holes that might allow intrusions by the Chinese or others.</p>
<p>And since last year, G42 has been training its advanced AI models in data centers in California and Texas through a commercial partnership with AI chip maker Cerebras, as it builds its infrastructure in the UAE.</p>
<p>In a sign of the region's growing tech importance, Microsoft in April made a $1.5 billion investment in G42, a move that drew some criticism in Washington because of the UAE firm's past investments in Chinese AI ventures and whether that could lead to intellectual property and advanced hardware flowing to America's most powerful rival. Microsoft President Brad Smith joined G42's board of directors.</p>
<p>G42 and Nvidia declined to comment.</p>
<p>Semafor <a href="https://www.semafor.com/article/09/11/2024/us-closer-to-green-lighting-nvidia-chips-for-saudi-arabia">reported</a> earlier this week that a likely approval for Nvidia chips is drawing nearer for Saudi Arabia.</p>


Contracts

Global

NVDA

"How The UAE Got The U.S. To Bless Its AI Ambitions; The U.S. Has Approved The Sale Of Nvidia Chips To G42, The Company At The Center Of The UAE's Efforts To Become A Global Leader In AI" - Semafor

<p>B of A Securities  analyst Curtis Nagle   maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Buy and raises the price target from $310 to $359.</p>


B of A Securities Maintains Buy on RH, Raises Price Target to $359

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>e.l.f. Beauty</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ELF, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for e.l.f. Beauty.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 25% bullish and 62%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $85,560, and 6 are calls, for a total amount of $205,694.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $240.0 for e.l.f. Beauty over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for e.l.f. Beauty's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across e.l.f. Beauty's significant trades, within a strike price range of $110.0 to $240.0, over the past month.</p>
<h3>e.l.f. Beauty Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726247322_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ELF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$122.3</td>
<td>$120.2</td>
<td>$121.0</td>
<td>$240.00</td>
<td>$60.5K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$16.7</td>
<td>$15.5</td>
<td>$15.85</td>
<td>$120.00</td>
<td>$55.4K</td>
<td style="text-align: right;">235</td>
<td style="text-align: right;">48</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$22.0</td>
<td>$21.5</td>
<td>$21.5</td>
<td>$115.00</td>
<td>$32.2K</td>
<td style="text-align: right;">91</td>
<td style="text-align: right;">18</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$1.55</td>
<td>$1.45</td>
<td>$1.5</td>
<td>$155.00</td>
<td>$31.8K</td>
<td style="text-align: right;">166</td>
<td style="text-align: right;">233</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$28.8</td>
<td>$28.0</td>
<td>$28.08</td>
<td>$125.00</td>
<td>$30.8K</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">11</td>
</tr>
</tbody>
</table>
</p>
<h3>About e.l.f. Beauty</h3>
<p>e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan and cruelty-free cosmetics and skin care products. The Company's mission is to make the best of beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women which include eyeliner, mascara, false eyelashes, lipstick, the foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels. The products that the company sells are marketed under the e.l.f. Cosmetics, W3LL PEOPLE and Keys Soulcare brands. It carries out sales within the US and internationally, out of which maximum revenue is generated from the US.</p>
<p>Having examined the options trading patterns of e.l.f. Beauty, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of e.l.f. Beauty</h3>
<ul>
<li>Trading volume stands at 1,630,815, with ELF's price down by -1.08%, positioned at $113.43.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 47 days.</li>
</ul>
<h3>What The Experts Say On e.l.f. Beauty</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $192.2.</p>
<ul>
<li>Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for e.l.f. Beauty, targeting a price of $190. </li>
<li>Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on e.l.f. Beauty with a target price of $150. </li>
<li>An analyst from B. Riley Securities downgraded its action to Buy with a price target of $175. </li>
<li>Maintaining their stance, an analyst from DA Davidson continues to hold a Buy rating for e.l.f. Beauty, targeting a price of $223. </li>
<li>An analyst from DA Davidson persists with their Buy rating on e.l.f. Beauty, maintaining a target price of $223. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest e.l.f. Beauty options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

What the Options Market Tells Us About e.l.f. Beauty

<p>Financial giants have made a conspicuous bullish move on Deere. Our analysis of options history for Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 37% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $790,985, and 3 were calls, valued at $161,944.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $420.0 for Deere over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Deere stands at 241.6, with a total volume reaching 903.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Deere, situated within the strike price corridor from $300.0 to $420.0, throughout the last 30 days.</p>
<h3>Deere 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726247317_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$19.85</td>
<td>$16.6</td>
<td>$18.2</td>
<td>$300.00</td>
<td>$364.0K</td>
<td style="text-align: right;">265</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$11.95</td>
<td>$11.95</td>
<td>$300.00</td>
<td>$212.7K</td>
<td style="text-align: right;">308</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.45</td>
<td>$4.5</td>
<td>$6.45</td>
<td>$300.00</td>
<td>$93.5K</td>
<td style="text-align: right;">308</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$48.35</td>
<td>$43.75</td>
<td>$43.75</td>
<td>$420.00</td>
<td>$87.9K</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.4</td>
<td>$11.95</td>
<td>$11.95</td>
<td>$300.00</td>
<td>$83.6K</td>
<td style="text-align: right;">308</td>
<td style="text-align: right;">71</td>
</tr>
</tbody>
</table>
</p>
<h3>About Deere</h3>
<p>Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.</p>
<p>After a thorough review of the options trading surrounding Deere, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Deere's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 374,320, the DE's price is up by 1.38%, now at $392.33. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>What Analysts Are Saying About Deere</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $410.2.</p>
<ul>
<li>An analyst from Evercore ISI Group persists with their In-Line rating on Deere, maintaining a target price of $378. </li>
<li>Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on Deere with a target price of $410. </li>
<li>An analyst from Citigroup persists with their Neutral rating on Deere, maintaining a target price of $395. </li>
<li>Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $443.</li>
<li>An analyst from Morgan Stanley has decided to maintain their Overweight rating on Deere, which currently sits at a price target of $425. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Deere with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Smart Money Is Betting Big In Deere Options

<p>High-rolling investors have positioned themselves bearish on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CYTK often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Cytokinetics. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 22% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $78,210, and 8 calls, totaling $454,049.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for Cytokinetics, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Cytokinetics options trades today is 2869.17 with a total volume of 1,920.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Cytokinetics's big money trades within a strike price range of $55.0 to $75.0 over the last 30 days.</p>
<h3>Cytokinetics Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726247312_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.6</td>
<td>$4.1</td>
<td>$4.6</td>
<td>$55.00</td>
<td>$108.2K</td>
<td>4</td>
<td style="text-align: right;">408</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.7</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$79.5K</td>
<td>13.0K</td>
<td style="text-align: right;">348</td>
</tr>
<tr>
<td>CYTK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.3</td>
<td>$2.9</td>
<td>$3.3</td>
<td>$55.00</td>
<td>$78.2K</td>
<td>312</td>
<td style="text-align: right;">450</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.6</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$52.0K</td>
<td>13.0K</td>
<td style="text-align: right;">303</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$8.8</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$60.00</td>
<td>$46.4K</td>
<td>1.4K</td>
<td style="text-align: right;">32</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cytokinetics</h3>
<p>Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.</p>
<p>Having examined the options trading patterns of Cytokinetics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Cytokinetics's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 246,671, the CYTK's price is up by 3.37%, now at $55.88. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cytokinetics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


CYTK

Cytokinetics's Options Frenzy: What You Need to Know

<p>B of A Securities  analyst Brad Sills   reiterates Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) with a Buy and maintains $640 price target.</p>


Reiteration

ADBE

B of A Securities Reiterates Buy on Adobe, Maintains $640 Price Target

<p>Cannabis investors should take note that investor <a href="https://www.benzinga.com/cannabis">sentiment in the industry</a> has shifted from bullish to neutral, according to the latest <strong>ATB Cannabis Investor Sentiment Survey</strong>.</p>
<p>The report, based on responses from institutional investors, reveals that only 31.8% of <a href="https://www.benzinga.com/markets/cannabis/24/08/40472079/investor-confidence-in-cannabis-is-amped-up-as-vcs-and-private-equity-firms-shift-perception-exp">investors remain optimistic </a>about the multi-state operator (MSO) sector, a sharp drop from the 83.3% recorded six months ago.</p>
<p>The primary reason for this change is the delay in uplistings to major U.S. exchanges, and also in moving cannabis to Schedule III. As a result of shifting expectations, just 9.1% of respondents reported increasing their exposure to the MSO sector in the past six months, compared to 61.1% in the spring of 2024.</p>
<h3 class="wp-block-heading">Cannabis Investor Sentiment Turns Neutral</h3>
<p>Uplisting to U.S. exchanges remains the top priority for 59.1% of investors, down from 73.7% six months ago, signaling some hesitation. Rescheduling to Schedule III ranks second, with 31.8% of investors citing it as a major driver for future investments.</p>
<p>But, despite the noticeable decline among bulls, the sentiment has not fully transitioned to pessimism. In fact, the survey highlights a more neutral stance as investors adopt a wait-and-see approach.</p>
<p>Key catalyst, such as <a href="https://www.benzinga.com/markets/cannabis/24/09/40846480/cannabis-experts-say-weed-reform-is-a-race-against-time-is-the-dea-delaying-bidens-rescheduling-">rescheduling cannabis</a> and uplisting companies to NASDAQ and NYSE, might reignite investor interest and turn the tide for cannabis industry leaders.</p>
<p>&#8220;Investors are holding back due to the delays in these key developments,&#8221; states the report, shared via an email to Benzinga Cannabis.</p>
<p><strong>Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/08/40472079/investor-confidence-in-cannabis-is-amped-up-as-vcs-and-private-equity-firms-shift-perception-exp"> Investor Confidence In Cannabis Is &#8216;Amped Up&#8217; As VCs And Private Equity Firms Shift Perception, Expert Says</a></strong></p>
<h3 class="wp-block-heading">Florida Legalization And Canadian Market Challenges</h3>
<p>Some pessimism might also be affecting <a href="https://www.benzinga.com/markets/cannabis/24/07/39871979/floridas-medical-cannabis-market-sees-explosive-growth-ahead-of-november-legalization-ballot">newer markets</a>.</p>
<p>The survey also found that Florida's cannabis legalization prospects have dimmed slightly, with investors assigning a 62% probability for adult-use legalization, down from 69% in the previous survey. This decline contrasts with expectations, as recent political discussions suggested growing support for legalization.</p>
<p>Despite the setback, many believe that the <a href="https://www.benzinga.com/markets/cannabis/24/09/40798916/desantis-vs-trump-over-florida-cannabis-legalization-guess-whos-winning">Florida market</a> could still present opportunities in the coming years.</p>
<p>Meanwhile, the sentiment towards the Canadian cannabis market has worsened significantly. </p>
<p>In the survey, 39% of respondents reported becoming more bearish on <a href="https://www.benzinga.com/markets/cannabis/24/07/39806043/cannabis-stocks-canadian-companies-outperformed-american-counterparts-last-week">Canadian companies</a>, up from 29% six months ago. Failed excise tax reform and the inability to access the U.S. cannabis market have contributed to this negative outlook. Investors highlighted that without regulatory changes, Canadian cannabis companies are struggling to gain momentum.</p>
<p><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</em></strong></p>
<h3 class="wp-block-heading">A Rebound For Investors Might Come</h3>
<p>Although the current sentiment is neutral, some cannabis investors are optimistic about the potential for a rebound if these long-awaited changes materialize. </p>
<p>Should rescheduling occur, 53.3% of respondents believe that the<strong> AdvisorShares Pure US Cannabis ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) could rise above $20, a substantial increase from its current level of $6.86.</p>
<p>At the same time, a majority of respondents (59.1%) see<a href="https://www.benzinga.com/markets/cannabis/23/05/32129949/tier-one-msos-gain-most-on-safe-act-reintroduction"> Tier 1 MSOs</a> as undervalued, suggesting a buying opportunity for those with a long-term view.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40427128/verano-green-thumb-marimeds-strong-q2-unpacking-the-cannabis-earnings-surge">Verano, Green Thumb &amp; MariMed&#8217;s Strong Q2: Unpacking The Cannabis Earnings Surge</a></strong></li>
</ul>
<p><em>Cover: AI generated image</em></p>


Cannabis

Economics

MSOS

Cannabis Investor Sentiment Softens As Institutional Confidence Wanes, Survey Shows

Macro Economic Events

Econ #s

U.S. Baker Hughes Oil Rig Count +5; U.S. Baker Hughes NatGas Rig Count +3; U.S. Baker Hughes Total Rig Count 590 Vs 582 Prior

<p>5 analysts have shared their evaluations of Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Signet Jewelers, presenting an average target of $96.8, a high estimate of $105.00, and a low estimate of $87.00. Observing a downward trend, the current average is 8.68% lower than the prior average price target of $106.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246919_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Signet Jewelers. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$87.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$87.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Signet Jewelers. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Signet Jewelers compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Signet Jewelers's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SIG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Signet Jewelers analyst ratings.</strong></a></p>
<h2>All You Need to Know About Signet Jewelers</h2>
<p>Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-mall &amp; Outlet.</p>
<h3>Unraveling the Financial Story of Signet Jewelers</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Signet Jewelers's financials over 3 months reveals challenges. As of 30 April, 2024, the company experienced a decline of approximately <strong>-9.42%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Signet Jewelers's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-2.65%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Signet Jewelers's ROE excels beyond industry benchmarks, reaching <strong>-1.89%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Signet Jewelers's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.62%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Signet Jewelers's debt-to-equity ratio is below the industry average. With a ratio of <b>0.59</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Signet Jewelers Stock

<p>Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) has outperformed the market over the past 10 years by 2.93% on an annualized basis producing an average annual return of 13.7%. Currently, Welltower has a market capitalization of $79.12 billion. </p>
<p><strong>Buying $100 In WELL:</strong> If an investor had bought $100 of WELL stock 10 years ago, it would be worth <strong>$360.73</strong> today based on a price of $129.89 for WELL at the time of writing.</p>
<h3>Welltower's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246891_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


WELL

Here's How Much You Would Have Made Owning Welltower Stock In The Last 10 Years

<p>Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 3.99% on an annualized basis producing an average annual return of 17.28%. Currently, Goldman Sachs Gr has a market capitalization of $151.27 billion. </p>
<p><strong>Buying $1000 In GS:</strong> If an investor had bought $1000 of GS stock 5 years ago, it would be worth <strong>$2,205.14</strong> today based on a price of $479.00 for GS at the time of writing.</p>
<h3>Goldman Sachs Gr's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246886_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In Goldman Sachs Gr 5 Years Ago Would Be Worth Today

<p>5 analysts have shared their evaluations of Dun &amp; Bradstreet Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNB#NYSE">DNB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Dun &amp; Bradstreet Hldgs, presenting an average target of $13.16, a high estimate of $17.00, and a low estimate of $11.80. This current average has increased by 2.17% from the previous average price target of $12.88. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246875_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Dun &amp; Bradstreet Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.80</td>
<td>$10.40</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dun &amp; Bradstreet Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dun &amp; Bradstreet Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dun &amp; Bradstreet Hldgs's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DNB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dun &amp; Bradstreet Hldgs analyst ratings.</strong></a></p>
<h2>Discovering Dun &amp; Bradstreet Hldgs: A Closer Look</h2>
<p>Dun &amp; Bradstreet Holdings Inc is a provider of business decisioning data and analytics. The company operates in two segments: North America, which offers Finance &amp; Risk and Sales &amp; Marketing data, analytics, and business insights in the United States and Canada; and International, which offers Finance &amp; Risk and Sales &amp; Marketing data, analytics, and business insights directly in the U.K, Europe, Greater China, India and indirectly through its WWN alliances. The company generates maximum revenue from the North American region. Other services provided by the company include digital marketing, sales acceleration, and risk management among others.</p>
<h3>Breaking Down Dun &amp; Bradstreet Hldgs's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Dun &amp; Bradstreet Hldgs showcased positive performance, achieving a revenue growth rate of <strong>3.88%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Dun &amp; Bradstreet Hldgs's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-2.85%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dun &amp; Bradstreet Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.49%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Dun &amp; Bradstreet Hldgs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.18%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Dun &amp; Bradstreet Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.11</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Dun & Bradstreet Hldgs's Future

<p>Throughout the last three months, 11 analysts have evaluated Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $662.0, a high estimate of $874.00, and a low estimate of $170.00. This current average has decreased by 7.93% from the previous average price target of $719.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246867_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Cintas by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Adjusts</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Caydee Blankenship</td>
<td>CFRA</td>
<td>Adjusts</td>
<td>Sell</td>
<td>$170.00</td>
<td>$645.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$735.00</td>
<td>-</td>
</tr>
<tr>
<td>Oliver Davies</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Neutral</td>
<td>$670.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$874.00</td>
<td>$790.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$850.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$625.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Jasper Bibb</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$850.00</td>
<td>$775.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$798.00</td>
<td>$667.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$775.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$725.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cintas. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Cintas compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Cintas's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cintas's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTAS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cintas analyst ratings.</strong></a></p>
<h2>All You Need to Know About Cintas</h2>
<p>Cintas is positioned as a one-stop shop that rents/sells uniforms and ancillary products and services, such as mops, first aid kits, and fire inspections. In its core uniform and facility services unit (a majority of sales), Cintas provides uniform rental programs for items including office attire, custom-tailored apparel, flame-resistant clothing, lab coats, and other profession-specific clothing. Facilities products include the rental and sale of entrance mats, mops, shop towels, hand sanitizers, and restroom supplies. Cintas' remaining businesses include first aid and safety services, fire protection services, and uniform direct sales.</p>
<h3>Understanding the Numbers: Cintas's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Cintas's revenue growth over a period of 3 months has been noteworthy. As of 31 May, 2024, the company achieved a revenue growth rate of approximately <strong>8.16%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Cintas's net margin excels beyond industry benchmarks, reaching <strong>16.71%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Cintas's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>9.66%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Cintas's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.55%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Cintas's debt-to-equity ratio is below the industry average. With a ratio of <b>0.62</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CTAS

Analyst Expectations For Cintas's Future

IBKR

TSLA

CNBC Halftime Report Final Trades: Tesla, Interactive Brokers Group, Suncor Energy, iShares Core S&P Small-Cap ETF

<p>In the preceding three months, 8 analysts have released ratings for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.75, a high estimate of $25.00, and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 31.26% increase from the previous average price target of $16.57.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246831_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Hims &amp; Hers Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cherny</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jonna Kim</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims &amp; Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hims &amp; Hers Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Hims &amp; Hers Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims &amp; Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HIMS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Hims &amp; Hers Health analyst ratings.</strong></a></p>
<h2>About Hims &amp; Hers Health</h2>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.</p>
<h3>Hims &amp; Hers Health's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Hims &amp; Hers Health showcased positive performance, achieving a revenue growth rate of <strong>51.82%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Hims &amp; Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.21%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Hims &amp; Hers Health's ROE excels beyond industry benchmarks, reaching <strong>3.76%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Hims &amp; Hers Health's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.86%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Hims &amp; Hers Health's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)

<p>In the preceding three months, 5 analysts have released ratings for Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $53.2, along with a high estimate of $70.00 and a low estimate of $41.00. Highlighting a 1.12% decrease, the current average has fallen from the previous average price target of $53.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246823_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Alaska Air Gr's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Helane Becker</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Stephen Trent</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alaska Air Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alaska Air Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Alaska Air Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Alaska Air Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alaska Air Gr analyst ratings.</strong></a></p>
<h2>Discovering Alaska Air Gr: A Closer Look</h2>
<p>Alaska Air Group Inc operates two airlines, Alaska and Horizon in three operating segments. The Mainline segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico, and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements (CPA). The Horizon segment includes the capacity sold to Alaska under a CPA. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary and Mileage Plan passenger revenue.</p>
<h3>Breaking Down Alaska Air Gr's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Alaska Air Gr showcased positive performance, achieving a revenue growth rate of <strong>2.08%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Alaska Air Gr's net margin is impressive, surpassing industry averages. With a net margin of <strong>7.59%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.36%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Alaska Air Gr's ROA excels beyond industry benchmarks, reaching <strong>1.46%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Alaska Air Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.92</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Alaska Air Gr Through The Eyes Of 5 Analysts

<p>B of A Securities  analyst Andrew Obin   maintains Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) with a Neutral and raises the price target from $72 to $80.</p>


CARR

B of A Securities Maintains Neutral on Carrier Global, Raises Price Target to $80

<p>During the last three months, 9 analysts shared their evaluations of Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $138.56, a high estimate of $150.00, and a low estimate of $120.00. This upward trend is evident, with the current average reflecting a 4.88% increase from the previous average price target of $132.11.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726246811_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Natera by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$132.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Natera. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Natera's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Natera's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Natera analyst ratings.</strong></a></p>
<h2>Discovering Natera: A Closer Look</h2>
<p>Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.</p>
<h3>A Deep Dive into Natera's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Natera showcased positive performance, achieving a revenue growth rate of <strong>58.13%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Natera's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-9.06%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Natera's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-4.59%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-2.51%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Natera's debt-to-equity ratio is below the industry average at <strong>0.52</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTRA

Analyst Scoreboard: 9 Ratings For Natera

Getlink reports November shuttle traffic

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Urbanization stocks are a cohort of stocks I haven&rsquo;t spent much time thinking about in recent years. However, I am concerned about climate change, so I think it&rsquo;s time I start paying closer attention.</p>



<p>BlackRock was talking about <a href="https://www.visualcapitalist.com/investing-megatrend-rapid-urbanisation/">rapid urbanization</a> as far back as 2019, one of five megatrends expected to shape the future of the global economy.&nbsp;</p>




<p>&ldquo;Of these five fundamental forces shaping the future of society, rapid urbanization will likely have the biggest effect on how and where humans live, creating a myriad of investment opportunities in the process,&rdquo; BlackRock stated.&nbsp;</p>




<p>It pointed out that in 1900, 40% of the U.S. population lived in cities. By 2016, that had more than doubled to 82%. I&rsquo;m sure it&rsquo;s higher today.&nbsp;</p>



<p>The World Bank&rsquo;s Urban Development unit estimates that by 2050, more than two-thirds of the global population will live in cities. Further, approximately 80% of the global gross domestic product (GDP) is generated in cities.&nbsp;&nbsp;&nbsp;</p>



<p>As you walk about your city, open your eyes to the opportunities due to rapid urbanization. They&rsquo;re all around.</p>



<h2>Otis Worldwide (OTIS)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/12/otis-1600-300x169.jpg" alt="momentum stocks: a smartphone screen displaying the Otis Worldwide (OTIS) logo"><div>Source: rafapress/shutterstock.com</div></div>


<p>I get a daily email newsletter from a Toronto real estate developer. On Dec. 16, his blog post was about how many more people Toronto could house if its <a href="https://brandondonnelly.com/2023/12/16/this-is-how-many-more-people-toronto-could-house-if-it-increased-its-population-density/">population density</a> increased. He points out that if Toronto had the same population density as Paris, more than 13 million people would live there.</p>



<p>Although I&rsquo;ve lived in Halifax since 2018, I spent most of my 59-odd years in Toronto, the last nine in Leaside, a neighbourhood that detested density of any kind. But I digress.</p>



<p>What I&rsquo;m trying to say is that as cities grow and real estate goes more vertical rather than horizontal, elevators become vital to a building&rsquo;s success. That&rsquo;s <strong>Otis Worldwide&rsquo;s </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/otis-stock-quote/"><strong>OTIS</strong></a></span>) bread and butter.&nbsp;&nbsp;</p>



<p>The company&rsquo;s tagline is &ldquo;We give people freedom to connect and thrive in a taller, faster, smarter world.&rdquo;&nbsp;</p>



<p>The thing is, it makes more money each quarter from servicing elevators and escalators than it does from the sale of new equipment. In <a href="https://otisinvestors.com/files/doc_presentation/2023/2-3Q23-Otis-Earnings-Webcast_10-24-23-vF_.pdf">Q3 2023</a>, service revenue accounted for 59% of its overall revenue of $3.52 billion. Even better, its operating margin for service revenue was nearly 25%, more than 3x the margin for new sales.&nbsp;</p>



<p>And the last time I checked, you can say no to new equipment but can&rsquo;t put off servicing. Well, not if you don&rsquo;t want a lawsuit on your hands.&nbsp;</p>



<p>It&rsquo;s the ideal business to benefit from city growth.</p>



<h2>Getlink (GRPTY)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/virtual-city-skyscrapers-bloktopia-1600-300x169.png" alt="A 3D render of a virtual city environment."><div>Source: Immersion Imagery / Shutterstock.com</div></div>


<p>This last one isn&rsquo;t so much about city growth as it is about city dwellers wanting to move around and easily explore other parts of the world.&nbsp;</p>



<p><strong>Getlink </strong>(OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/grpty-stock-quote/"><strong>GRPTY</strong></a></span>) is the Paris-based company that owns Eurotunnel, the company that built the Chunnel, a <a href="https://en.wikipedia.org/wiki/Channel_Tunnel">31-mile tunnel</a> between Folkstone in the UK and Coquelles on the other side of the English Channel in France. It is the world&rsquo;s third-longest railway tunnel.</p>



<p>Getlink has the concession rights to operate the Chunnel infrastructure until 2086. Since 1994, more than <a href="https://www.getlinkgroup.com/content/uploads/2023/06/cp-q1-2023-vuk.pdf">481 million</a> people and 99 million vehicles have traveled through the Chunnel.</p>



<p>The company makes money in several ways.</p>



<p>First, <a href="https://www.getlinkgroup.com/content/uploads/2023/07/press-release-h1-2023.pdf">it generates revenue from LeShuttle</a>, its service shuttling passenger and freight vehicles between the two countries, and fees paid by the Eurostar high-speed trains using the Chunnel. Secondly, it owns the Europorte rail freight company, which profitably moves freight around France. Lastly, the newest revenue generator is ElecLink, the 1,000-megawatt (MW) electricity interconnector, which allows for the movement of electricity between the two countries. It launched in <a href="https://www.getlinkgroup.com/en/our-group/eleclink/">May 2022</a>.&nbsp;</p>



<p>In the first half of 2023, its Eurotunnel business generated 57% of its 934 million euros ($1.03 billion). ElecLink accounted for 35% and Europorte the remaining 8%. It generated 496 million euros ($547.3 million) before interest, taxes, depreciation and amortization (EBITDA), a high EBITDA margin of 53%.</p>



<p>The best part: GetLink does all of this in an <a href="https://www.eurotunnel.com/uk/travelling-with-us/environmentally-friendly-travel/">environmentally-friendly way</a>.&nbsp;</p>



<h2>Uber Technologies (UBER)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/uber1600-300x169.jpg" alt="The Uber logo is displayed on a smartphone on top of a map background."><div>Source: Proxima Studio / Shutterstock.com</div></div>


<p>No company speaks to city living more than <strong>Uber Technologies </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/uber-stock-quote/"><strong>UBER</strong></a></span>). Between its ride-hailing business and Uber Eats, its drivers probably spend more time on city streets than anyone except for emergency services personnel and sanitation workers.</p>



<p><em>Bloomberg </em>reported in September that the company was developing a service through the Uber app that allows users to order <a href="https://www.bloomberg.com/news/articles/2023-09-08/uber-working-on-taskrabbit-like-service-in-potential-expansion">tasks to be completed</a> with a minimum one-hour hire. The duties include appliance repair, cleaning, furniture assembly, and other potential household chores.&nbsp;</p>



<p>In October, it started a service to pick up packages that were being returned and to mail packages for customers for a flat fee of $5.&nbsp;&nbsp;&nbsp;</p>



<p>Uber is trying to become Amazon-like by providing as many services for city dwellers as possible, saving them time and aggravation.&nbsp;</p>



<p>The possibilities are limitless when you think about how much data and information it has about city dwellers worldwide. And it&rsquo;s all driven around the Uber app.&nbsp;</p>



<p><em>On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2023/12/3-urbanization-stocks-to-capitalize-on-city-growth-in-2024/">3 Urbanization Stocks to Capitalize on City Growth in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Getlink

News

Latest news for Getlink (OTC:GRPTY) Stock